Xiaoping S Liang from Conshohocken, PA, age 69

Vehicle Records

Xiaoping Liang
view source
Address:

5024 Woodgate Ln, Collegeville, PA 19426
VIN:

1HGCM66517A047714
Make:

HONDA
Model:

ACCORD
Year:

2007

Resumes

Xiaoping Liang

view source

Us Patents

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

7780963, Aug 24, 2010
Filed:

Oct 21, 2005
Appl. No.:

11/256332
Inventors:

Paul Acton - Quakertown PA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Lei Chang - Westmont IL, US
Elizabeth Chen Dodson - Souderton PA, US
Gene Kinney - Collegeville PA, US
William Klein - Winetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kirsten Viola - Chicago IL, US
Assignee:

Merck & Co., Inc. - Rahway NJ
Northwestern University - Evanston IL
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β1-42.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

7811563, Oct 12, 2010
Filed:

Oct 21, 2005
Appl. No.:

11/577426
Inventors:

Paul Acton - Quakertown PA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Elizabeth Chen Dodson - Souderton PA, US
Gene Kinney - Collegeville PA, US
William L Klein - Winetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kirsten Viola - Chicago IL, US
Lei Chang - Westmont IL, US
Assignee:

Northwestern University - Evanston IL
Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Peptide Conjugate Compositions And Methods For The Prevention And Treatment Of Alzheimer's Disease
view source
US Patent:

7850973, Dec 14, 2010
Filed:

May 1, 2006
Appl. No.:

11/919897
Inventors:

Victor M. Garsky - Blue Bell PA, US
Joseph G. Joyce - Lansdale PA, US
Paul M. Keller - Lansdale PA, US
Gene Kinney - Collegeville PA, US
Xiaoping Liang - Collegeville PA, US
John W. Shiver - Doylestown PA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/00
A61K 39/08
A61K 39/095
A61K 39/02
A61K 38/08
A61K 45/00
A61K 33/06
US Classification:

4241851, 42419711, 4242361, 4242471, 4242501, 4241821, 424682, 424698, 4242781, 4242821, 4242831
Abstract:

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

8128930, Mar 6, 2012
Filed:

Jul 1, 2010
Appl. No.:

12/828411
Inventors:

Paul Acton - Newbury Park CA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Lei Chang - Westmont IL, US
Elizabeth Chen Dodson - Soudertown PA, US
Gene Kinney - Collegeville PA, US
William L. Klein - Winnetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kristen Viola - Chicago IL, US
Assignee:

Northwestern University - Evanston IL
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 5303881, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Anti-Addl Antibodies And Uses Thereof
view source
US Patent:

8383113, Feb 26, 2013
Filed:

Feb 8, 2012
Appl. No.:

13/368742
Inventors:

Paul Acton - Quakertown PA, US
Zhiqiang An - Ambler PA, US
Andrew J. Bett - Lansdale PA, US
Robert Breese - Quakertown PA, US
Lei Chang - Westmont IL, US
Elizabeth Chen Dodson - Souderton PA, US
Gene Kinney - Collegeville PA, US
William Klein - Winetka IL, US
Mary P. Lambert - Glenview IL, US
Xiaoping Liang - Collegeville PA, US
Paul Shughrue - West Chester PA, US
William R. Strohl - Bridgewater NJ, US
Kristen Viola - Chicago IL, US
Assignee:

Northwestern University - Evanston IL
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
US Classification:

4241331, 5303873, 5303881, 435 72, 4241411
Abstract:

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

Polynucleotide Vaccines Expressing Codon Optimized Hiv-1 Nef And Modified Hiv-1 Nef
view source
US Patent:

20030096778, May 22, 2003
Filed:

Jun 13, 2002
Appl. No.:

10/149640
Inventors:

John Shiver - Chalfont PA, US
Xiaoping Liang - Eagleville PA, US
Tong-Ming Fu - Lansdale PA, US
International Classification:

A61K048/00
A61K039/00
US Classification:

514/044000, 424/184100
Abstract:

Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The nef-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and express the HIV Nef protein or biologically relevant portions thereof, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef modifications comprising amino terminal leader peptides, removal of the amino terminal myristylation site, and/or modification of the Nef dileucine motif. These modifications may effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4.

Influenza Virus Vaccine
view source
US Patent:

20040223976, Nov 11, 2004
Filed:

Mar 5, 2004
Appl. No.:

10/794646
Inventors:

Elisabetta Bianchi - Roma, IT
Victor Garsky - Blue Bell PA, US
Paolo Ingallinella - Roma, IT
Roxana Ionescu - Collegeville PA, US
Xiaoping Liang - Eagleville PA, US
Antonello Pessi - Roma, IT
Craig Przysiecki - Lansdale PA, US
Li Shi - Eagleville PA, US
John Shiver - Chalfont PA, US
International Classification:

A61K039/12
A61K039/21
C07K014/11
US Classification:

424/186100, 530/350000
Abstract:

The present invention provides vaccines against disease caused by infection with influenza virus, and methods of vaccination. The vaccines comprise peptides derived from the M2 and/or HA proteins of influenza virus conjugated to a carrier protein.

Method Of Inducing An Enhanced Immune Response Against Hiv
view source
US Patent:

20050106123, May 19, 2005
Filed:

Mar 12, 2003
Appl. No.:

10/507098
Inventors:

Emilio Emini - Wayne PA, US
John Shiver - Chalfont PA, US
Michael Chastain - Erdenheim PA, US
Danilo Casimiro - Harley PA, US
Tong-Ming Fu - Ambler PA, US
Xiaoping Liang - Eagleville PA, US
International Classification:

A61K048/00
A61K039/12
C12N015/867
US Classification:

424093200, 424199100, 435456000
Abstract:

An efficient means of inducing an immune response against human immunodeficiency virus (“HIV”) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol wherein recombinant adenoviral and poxvirus vectors comprising exogenous genetic material encoding a common HIV antigen are administered in that order. Vaccines administered into living vertebrate tissue in accordance with the disclosed regimes, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 antigen (e.g., Gag), inducing a cellular immune response which specifically recognizes HIV-1. It is believed that the disclosed prime/boost regime will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.